Physician profile
Olga Romanovsky
NPI 1245648401
$2,403.64
in general payments reported to CMS, 2019-2025
14 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $207 · 2021: $204 · 2022: $338 · 2023: $336 · 2024: $395 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $671.57 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $495.83 | 2022-2025 | Xiidra, Infuse, Biotrue |
| Alcon Vision LLC | $306.74 | 2019-2025 | Total30, Precision 1, Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $255.60 | 2019-2021 | |
| Coopervision INC. | $157.72 | 2019-2025 | Misight Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $137.36 | 2019-2020 | |
| Dompe US, INC. | $113.12 | 2022-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $73.25 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $59.19 | 2020-2021 | |
| Astellas Pharma US INC | $51.48 | 2024 | Izervay |
| Thea Pharma INC. | $24.01 | 2024 | Iyuzeh |
| Abbvie INC. | $23.67 | 2022 | |
| Oasis Medical, INC. | $19.68 | 2023 | Oasis Tears |
| Abb Con-Cise Optical Group LLC | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Romanovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.